Medical groups question price of new hep C drug

An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care experts, as they consider whether it is worth the $1,000-a-pill price set by manufacturer Gilead Sciences.

A panel of California medical experts voted Monday that Gilead's Sovaldi represents a "low value" treatment when compared with older drugs for the blood borne virus. The vote was part of a broader review of new hepatitis C drugs by the California Technology Assessment Forum. The insurer-affiliated group assesses the and effectiveness of new medical treatments.

The group estimates that replacing currently used hepatitis C drugs with Gilead's Sovaldi would raise California drug costs between $18 billion and $29 billion per year. The drug costs $84,000 for one 12-week course of treatment.


Explore further

US approves breakthrough hepatitis C drug (Update)

© 2014 The Associated Press. All rights reserved.

Citation: Medical groups question price of new hep C drug (2014, March 11) retrieved 24 June 2019 from https://medicalxpress.com/news/2014-03-medical-groups-price-hep-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more